Get the Stockscreener App
3.06
1.29%
-0.04
Protara Therapeutics Inc stock is traded at $3.06, with a volume of 301.82K.
It is down -1.29% in the last 24 hours and up +9.29% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$3.10
Open:
$3.05
24h Volume:
301.82K
Relative Volume:
0.89
Market Cap:
$118.06M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-1.0851
EPS:
-2.82
Net Cash Flow:
$-35.26M
1W Performance:
-8.11%
1M Performance:
+9.29%
6M Performance:
-37.80%
1Y Performance:
+45.02%
1-Day Range:
$3.012
$3.28
1-Week Range:
$3.012
$3.568
52-Week Range:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.06 | 119.60M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Combining price and volume data for Protara Therapeutics Inc.Free Verified Signal From Chart Patterns - Newser
Why Protara Therapeutics Inc. stock attracts strong analyst attentionEntry Optimization Guide with Volume Analysis - Newser
How to build a custom watchlist for Protara Therapeutics Inc.Long Hold Investment Strategy with Growth Focus - Newser
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Protara Therapeutics Grants $45K Worth of Stock Options and RSUs to Strategic New Employees - Stock Titan
Understanding Protara Therapeutics Inc.’s price movementFree Stable Entry High Return Opportunities - Newser
News impact scoring models applied to Protara Therapeutics Inc.Risk-Managed Swing Setup and Signal Analysis - Newser
What earnings revisions data tells us about Protara Therapeutics Inc.Intraday Movement Recap and Chart Summary - Newser
How Protara Therapeutics Inc. stock performs during market volatilityShort-Term Growth Watch with Signal Prediction - Newser
What catalysts could drive Protara Therapeutics Inc. stock higher in 2025Daily Trading Forecasts For Consistent Profits - jammulinksnews.com
Key External Factors That Drive Protara Therapeutics Inc. Stock Price MovementsRisk Managed Watchlist with Breakout Picks - Newser
Does Protara Therapeutics Inc. fit your quant trading modelAI Generated Momentum Stock Forecast Guide - Newser
Intrinsic Value of Protara Therapeutics Inc. Stock: Is It Undervalued or OvervaluedDaily Market Momentum Summary and Strategy - Newser
Fibonacci Retracement Aligns with Support in Protara Therapeutics Inc.Reliable Alerts for Daily Stock Movers Released - metal.it
Is Protara Therapeutics Inc. a growth stock or a value stockAchieve breakthrough results with expert guidance - jammulinksnews.com
What is the dividend policy of Protara Therapeutics Inc. stockExceptional earning trajectories - jammulinksnews.com
How strong is Protara Therapeutics Inc. company’s balance sheetAchieve consistent double-digit returns - jammulinksnews.com
Why is Protara Therapeutics Inc. stock attracting strong analyst attentionFree Investment Timing Strategies - jammulinksnews.com
What institutional investors are buying Protara Therapeutics Inc. stockHigh-velocity gains - jammulinksnews.com
What makes Protara Therapeutics Inc. stock price move sharplyRapid capital growth - jammulinksnews.com
How does Protara Therapeutics Inc. generate profit in a changing economySuperior investment outcomes - jammulinksnews.com
How does Protara Therapeutics Inc. compare to its industry peersUnlock powerful trading tools for investors - jammulinksnews.com
Analysts Set Protara Therapeutics, Inc. (NASDAQ:TARA) Price Target at $20.50 - Defense World
Does Protara Therapeutics Inc. stock perform well during market downturnsUnlock powerful trading signals and alerts - jammulinksnews.com
Published on: 2025-07-27 23:52:26 - jammulinksnews.com
What are the technical indicators suggesting about Protara Therapeutics Inc.Rapid growth opportunities - jammulinksnews.com
What are analysts’ price targets for Protara Therapeutics Inc. in the next 12 monthsDiscover high-return stocks for your portfolio - jammulinksnews.com
Is Protara Therapeutics Inc. a good long term investmentTriple-digit profit margins - PrintWeekIndia
What drives Protara Therapeutics Inc. stock priceDynamic profit expansion - PrintWeekIndia
Protara Therapeutics Inc. Stock Analysis and ForecastUnprecedented profits - Autocar Professional
Should I buy Protara Therapeutics Inc. stock before earningsSuperior profit margins - jammulinksnews.com
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):